EC
XLRN

EcoR1 Capital’s Acceleron Pharma XLRN Stock Holding History

EcoR1 Capital’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-371,381
Closed -$12.6M – 43
2016
Q2 		$12.6M Buy
371,381
+101,092
+37% +$3.29M 4.98% 7
2016
Q1 		$7.13M Buy
+270,289
New +$7.86M 2.49% 15

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

EcoR1 Capital's XLRN Position: Q3 2016 in Review

EcoR1 Capital sold out of Acceleron Pharma (XLRN) in Q3 2016, closing a stake of 371,381 shares — an estimated $12.6M sold.

EcoR1 Capital first reported a position in XLRN in Q1 2016 and held it in 2 quarters. The position peaked at $12.6M in Q2 2016. 139 funds tracked by Wall St. Rank hold XLRN as of Q3 2016.

  • EcoR1 Capital reported no remaining Acceleron Pharma position as of Q3 2016 after selling out during the quarter.
  • EcoR1 Capital sold 371,381 Acceleron Pharma shares in Q3 2016, an estimated $12.6M.
  • EcoR1 Capital first reported a position in Acceleron Pharma in Q1 2016 and held it in 2 quarters.
  • EcoR1 Capital's Acceleron Pharma position peaked at $12.6M in Q2 2016.
  • 139 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2016.

Based on EcoR1 Capital's 13F filing for Q3 2016, filed 14 Nov 2016.